<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Cardiovasc Med</journal-id><journal-id journal-id-type="iso-abbrev">Front Cardiovasc Med</journal-id><journal-id journal-id-type="publisher-id">Front. Cardiovasc. Med.</journal-id><journal-title-group><journal-title>Frontiers in Cardiovascular Medicine</journal-title></journal-title-group><issn pub-type="epub">2297-055X</issn><publisher><publisher-name>Frontiers Media S.A.</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40401225</article-id><article-id pub-id-type="pmc">PMC12092362</article-id><article-id pub-id-type="doi">10.3389/fcvm.2025.1557909</article-id><article-categories><subj-group subj-group-type="heading"><subject>Cardiovascular Medicine</subject><subj-group><subject>Original Research</subject></subj-group></subj-group></article-categories><title-group><article-title>Prognostic value of lactate clearance, fluid balance, and APACHE II score in patients with cardiogenic shock receiving extracorporeal membrane oxygenation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Qi-Feng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/><role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Shuang-Long</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Gang</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Guo</surname><given-names>Miao</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Qi</surname><given-names>Xiao-Xia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author"><name><surname>Xing</surname><given-names>Xiao-Hui</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/data-curation/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Zheng</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp">*</xref><uri xlink:href="https://loop.frontiersin.org/people/2547971/overview"/><role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/><role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/><role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/></contrib></contrib-group><aff id="aff1"><label><sup>1</sup></label><institution>Department of Critical Care Medicine, Peking University International Hospital</institution>, <addr-line>Beijing</addr-line>, <country>China</country></aff><aff id="aff2"><label><sup>2</sup></label><institution>Department of Neurosurgery, Tianjin Medical University General Hospital</institution>, <addr-line>Tianjin</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p><bold>Edited by:</bold> Ricardo Mourilhe-Rocha, Rio de Janeiro State University, Brazil</p></fn><fn fn-type="edited-by"><p><bold>Reviewed by:</bold> Eduesley Santana-Santos, Graduate Nursing Program/Federal University of Sergipe, Brazil</p><p>Warwick Wolf Butt, Royal Children&#x02019;s Hospital, Australia</p></fn><corresp id="cor1"><label>*</label><bold>Correspondence:</bold> Zheng Wang <email>ZhengWangwz@outlook.com</email></corresp></author-notes><pub-date pub-type="epub"><day>07</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><elocation-id>1557909</elocation-id><history><date date-type="received"><day>09</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>14</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Zhang, Zhang, Li, Guo, Qi, Xing and Wang.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Zhang, Zhang, Li, Guo, Qi, Xing and Wang</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License (CC BY)</ext-link>. The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><abstract><sec><title>Objective</title><p>The objective of this study is to examine the prognostic value of lactate clearance, fluid balance, and the Acute Physiology and Chronic Health Evaluation II (APACHE II) score in patients with cardiogenic shock undergoing treatment with extracorporeal membrane oxygenation (ECMO).</p></sec><sec><title>Methods</title><p>A retrospective analysis was conducted on 32 patients with cardiogenic shock who underwent ECMO in the Intensive Care Unit of Peking University International Hospital between January 2021 and June 2024. The patients were categorized into a survival group (<italic>n</italic>&#x02009;=&#x02009;14) and a non-survival group (<italic>n</italic>&#x02009;=&#x02009;18) based on their clinical outcomes. Baseline characteristics, including age, sex, and body weight and so on were collected for both groups. Multivariate logistic regression analysis was used to identify risk factors influencing patient prognosis. The prognostic value of relevant indicators was assessed using receiver operating characteristic curve analysis, while Pearson's correlation analysis was conducted to assess the relationships between specific indicators.</p></sec><sec><title>Results</title><p>Lactate clearance was significantly lower in the non-survival group compared to the survival group, while fluid balance and APACHE II scores were notably higher in the non-survival group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). Based on the predictive model, the APACHE II score demonstrated the highest specificity for prognosis at 97.4%, whereas the combined indices exhibited the highest sensitivity at 95.5%. Additionally, lactate clearance revealed a negative correlation with both fluid balance and APACHE II scores (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05).</p></sec><sec><title>Conclusion</title><p>This pilot study demonstrated that lactate clearance, fluid balance, and APACHE II score are valuable prognostic indicators for patients; however, the predictive accuracy of individual indicators is limited. The combined assessment of these indices provides a more robust and reliable predictive performance.</p></sec></abstract><kwd-group><kwd>cardiogenic shock</kwd><kwd>extracorporeal membrane oxygenation therapy</kwd><kwd>fluid balance</kwd><kwd>lactate clearance</kwd><kwd>APACHE II score</kwd></kwd-group><funding-group><funding-statement>The author(s) declare that no financial support was received for the research and/or publication of this article.</funding-statement></funding-group><counts><fig-count count="2"/><table-count count="4"/><equation-count count="1"/><ref-count count="12"/><page-count count="7"/><word-count count="0"/></counts><custom-meta-group><custom-meta><meta-name>section-at-acceptance</meta-name><meta-value>Intensive Care Cardiovascular Medicine</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><label>1</label><title>Introduction</title><p>Cardiogenic shock is a clinical syndrome characterized by a sudden decrease in cardiac output and subsequent hypoperfusion of tissues and organs, posing a severe threat to patient health due to metabolic disturbances and damage to critical organs (<xref rid="B1" ref-type="bibr">1</xref>). The condition often leads to ischemic injury and necrosis of vital tissues and organs, necessitating timely and effective medical interventions. Advances in cardiopulmonary assist technologies have led to the development of extracorporeal membrane oxygenation (ECMO), which provides vital support for the management of cardiogenic shock disease (<xref rid="B2" ref-type="bibr">2</xref>). ECMO functions by delivering cardiopulmonary support through extracorporeal medical devices, providing potential improvement in clinical outcomes for patients who are critically ill (<xref rid="B3" ref-type="bibr">3</xref>).</p><p>However, clinical experience highlights significant variability among patients with cardiogenic shock, where prognosis is influenced by multiple factors (<xref rid="B4" ref-type="bibr">4</xref>). Thus, it is essential to adopt not only scientifically validated interventions but also comprehensive prognostic assessments to optimize outcomes and meet the personalized treatment needs of patients.</p><p>Lactate levels, a common marker of tissue perfusion, are significantly elevated during disease states, and lactate clearance serves as an important indicator of metabolic efficiency and disease severity. Fluid balance reflects the fluid retention and load of the body, while the APACHE II score provides a standardized measure of disease severity. This study posits that these three parameters hold significant value in prognostic evaluation. Exploring their predictive efficacy is, therefore, of substantial clinical and research importance.</p></sec><sec id="s2"><label>2</label><title>General data and method</title><sec id="s2a"><label>2.1</label><title>General data</title><p>A retrospective analysis was conducted on 32 patients with cardiogenic shock who received ECMO in the Intensive Care Unit of Peking University International Hospital. These patients were categorized into a survival group (<italic>n</italic>&#x02009;=&#x02009;14) and a non-survival group (<italic>n</italic>&#x02009;=&#x02009;18) based on their clinical outcomes. A comparison of baseline characteristics is presented in <xref rid="T1" ref-type="table">Table&#x000a0;1</xref>.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Comparison of general data of patients (n, %), (<inline-formula><mml:math id="IM1" overflow="scroll"><mml:mrow><mml:mover><mml:mi>x</mml:mi><mml:mo stretchy="false">&#x000af;</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula>&#x000b1;s).</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" colspan="2" rowspan="1">Index</th><th valign="top" align="center" rowspan="1" colspan="1">Survival group (<italic>n</italic>&#x02009;=&#x02009;14)</th><th valign="top" align="center" rowspan="1" colspan="1">Non-survival group (<italic>n</italic>&#x02009;=&#x02009;18)</th><th valign="top" align="center" rowspan="1" colspan="1"><italic>&#x003c7;<sup>2</sup></italic>/<italic>t</italic></th><th valign="top" align="center" rowspan="1" colspan="1">
<italic>P</italic>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="2" colspan="1">Sex</td><td valign="top" align="center" rowspan="1" colspan="1">Male</td><td valign="top" align="center" rowspan="1" colspan="1">8 (57.14)</td><td valign="top" align="center" rowspan="1" colspan="1">12 (66.66)</td><td valign="top" align="center" rowspan="2" colspan="1">0.287</td><td valign="top" align="center" rowspan="2" colspan="1">0.592</td></tr><tr><td valign="top" align="center" rowspan="1" colspan="1">Female</td><td valign="top" align="center" rowspan="1" colspan="1">6 (42.85)</td><td valign="top" align="center" rowspan="1" colspan="1">6 (33.33)</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Age (years)</td><td valign="top" align="center" rowspan="1" colspan="1">72.83&#x02009;&#x000b1;&#x02009;6.11</td><td valign="top" align="center" rowspan="1" colspan="1">73.45&#x02009;&#x000b1;&#x02009;6.02</td><td valign="top" align="center" rowspan="1" colspan="1">0.381</td><td valign="top" align="center" rowspan="1" colspan="1">0.705</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Body weight (kg/m<sup>2</sup>)</td><td valign="top" align="center" rowspan="1" colspan="1">26.23&#x02009;&#x000b1;&#x02009;2.44</td><td valign="top" align="center" rowspan="1" colspan="1">26.15&#x02009;&#x000b1;&#x02009;2.36</td><td valign="top" align="center" rowspan="1" colspan="1">0.124</td><td valign="top" align="center" rowspan="1" colspan="1">0.902</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Blood potassium (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">4.62&#x02009;&#x000b1;&#x02009;1.22</td><td valign="top" align="center" rowspan="1" colspan="1">4.68&#x02009;&#x000b1;&#x02009;1.35</td><td valign="top" align="center" rowspan="1" colspan="1">0.177</td><td valign="top" align="center" rowspan="1" colspan="1">0.860</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Blood sodium (mmol/L)</td><td valign="top" align="center" rowspan="1" colspan="1">140.35&#x02009;&#x000b1;&#x02009;6.38</td><td valign="top" align="center" rowspan="1" colspan="1">141.22&#x02009;&#x000b1;&#x02009;6.51</td><td valign="top" align="center" rowspan="1" colspan="1">0.505</td><td valign="top" align="center" rowspan="1" colspan="1">0.615</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Prothrombin activity (%)</td><td valign="top" align="center" rowspan="1" colspan="1">62.83&#x02009;&#x000b1;&#x02009;11.57</td><td valign="top" align="center" rowspan="1" colspan="1">64.32&#x02009;&#x000b1;&#x02009;12.37</td><td valign="top" align="center" rowspan="1" colspan="1">0.469</td><td valign="top" align="center" rowspan="1" colspan="1">0.641</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Sequential Organ Failure Assessment (points)</td><td valign="top" align="center" rowspan="1" colspan="1">15.35&#x02009;&#x000b1;&#x02009;3.68</td><td valign="top" align="center" rowspan="1" colspan="1">15.88&#x02009;&#x000b1;&#x02009;3.95</td><td valign="top" align="center" rowspan="1" colspan="1">0.523</td><td valign="top" align="center" rowspan="1" colspan="1">0.603</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">pH value</td><td valign="top" align="center" rowspan="1" colspan="1">7.28&#x02009;&#x000b1;&#x02009;0.33</td><td valign="top" align="center" rowspan="1" colspan="1">7.34&#x02009;&#x000b1;&#x02009;0.32</td><td valign="top" align="center" rowspan="1" colspan="1">0.686</td><td valign="top" align="center" rowspan="1" colspan="1">0.495</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Lactate clearance (%)</td><td valign="top" align="center" rowspan="1" colspan="1">39.19&#x02009;&#x000b1;&#x02009;14.66</td><td valign="top" align="center" rowspan="1" colspan="1">19.13&#x02009;&#x000b1;&#x02009;10.13</td><td valign="top" align="center" rowspan="1" colspan="1">5.672</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">Fluid balance (ml/kg)</td><td valign="top" align="center" rowspan="1" colspan="1">20.73&#x02009;&#x000b1;&#x02009;6.34</td><td valign="top" align="center" rowspan="1" colspan="1">25.66&#x02009;&#x000b1;&#x02009;6.01</td><td valign="top" align="center" rowspan="1" colspan="1">2.957</td><td valign="top" align="center" rowspan="1" colspan="1">0.004</td></tr><tr><td valign="top" align="left" colspan="2" rowspan="1">APACHE II score (points)</td><td valign="top" align="center" rowspan="1" colspan="1">10.47&#x02009;&#x000b1;&#x02009;2.80</td><td valign="top" align="center" rowspan="1" colspan="1">15.04&#x02009;&#x000b1;&#x02009;3.13</td><td valign="top" align="center" rowspan="1" colspan="1">5.834</td><td valign="top" align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr></tbody></table></table-wrap></sec><sec id="s2b"><label>2.2</label><title>Inclusion and exclusion criteria</title><p>Inclusion Criteria: (1) Patients meeting the diagnostic criteria for cardiogenic shock (<xref rid="B5" ref-type="bibr">5</xref>); (2) Diagnosis of cardiogenic shock confirmed by echocardiography and microcirculatory perfusion assessments; (3) Patients with low tissue perfusion; (4) Ineffectiveness of fluid resuscitation and blood volume supplementation, necessitating ECMO; and (5) Cardiogenic shock primarily caused by underlying heart disease.</p><p>Exclusion Criteria: (1) Recent treatment with nitroprusside or metformin; (2) Presence of other malignant tumors, severely impaired renal function, metabolic disorders, significant traumatic brain injury, cerebral hemorrhage, or drug intoxication; (3) Decision by the family to give up active treatment.</p></sec><sec sec-type="methods" id="s2c"><label>2.3</label><title>Methods</title><list list-type="simple"><list-item><label>(1)</label><p>Preparation for ECMO: The ECMO equipment and associated pipelines were coated with heparin. Percutaneous punctures of the femoral artery and femoral vein were conducted sequentially, followed by the insertion of an 18F arterial drainage cannula and an 18F venous drainage cannula. The veno-arterial (V-A) mode was selected for the procedure.</p></list-item><list-item><label>(2)</label><p>Operational Management: During the ECMO procedure, arterial blood gas levels of the patient were monitored every six hours to ensure that arterial blood oxygen saturation remains above 95%. Unfractionated heparin was administered as an anticoagulant, with dosage adjustments made, based on whole blood activated coagulation time. Pump flow, ventilation strategies, and vasoactive drug regimens were adjusted in response to changes in blood oxygenation and hemodynamic parameters.</p></list-item><list-item><label>(3)</label><p>Weaning from ECMO: Weaning was initiated when the ECMO flow was&#x02009;&#x0003c;&#x02009;10% of cardiac output, blood pressure&#x02009;&#x0003e;&#x02009;80&#x02005;mmHg with a pulse pressure&#x02009;&#x0003e;&#x02009;20&#x02005;mmHg after discontinuation of vasoactive drugs, and vital signs remained stable for a period exceeding six hours. These conditions were mandatory to proceed with weaning.</p></list-item></list><p>Therapeutic goals were guided by clinical protocols for managing cardiogenic shock and individualized physician assessments. Institutional guidelines set targets of systolic blood pressure &#x02265;90&#x02005;mmHg and a cardiac index &#x02265;2.2&#x02005;L/min/m<sup>2</sup> to optimize tissue perfusion and organ function during ECMO support.</p></sec><sec id="s2d"><label>2.4</label><title>Survey tools and data collection</title><p>Upon admission, data collected included age, sex, body weight, serum potassium, serum sodium, prothrombin activity, Sequential Organ Failure Assessment (SOFA) score, potential of hydrogen (pH), lactate clearance, fluid balance, and APACHE II score. Among them, serum potassium and sodium levels were measured using electrolyte analysis, with normal reference ranges of 3.5&#x02013;5.5&#x02005;mmol/L and 135&#x02013;145&#x02005;mmol/L, respectively. Coagulation was assessed through prothrombin activity measurement, with a normal range of 70%&#x02013;130%. The SOFA score was analyzed, with a total scoring range of 0&#x02013;24 points (<xref rid="B6" ref-type="bibr">6</xref>). Arterial blood samples were analyzed using a blood gas biochemistry analyzer to determine pH levels and lactate clearance. The normal pH range was 6.9&#x02013;7.7. Lactate clearance was calculated using the formula: (initial value&#x02014;retest value)/initial value * 100%. The formula for calculating the liquid balance is (total liquid input&#x02014;total output for 24&#x02005;h on the machine)/body weight. The APACHE II score incorporated factors such as age, type of surgery, function of vital organs, and physiological abnormalities, with scoring based on clinical presentation (<xref rid="B7" ref-type="bibr">7</xref>).</p></sec><sec id="s2e"><label>2.5</label><title>Statistical analysis</title><p>Statistical analysis was conducted using SPSS version 24.0. Measurement data with a normal distribution, including age, body weight, serum potassium, serum sodium, prothrombin activity, SOFA score, pH value, lactate clearance, fluid balance, and APACHE II score, are expressed as mean&#x02009;&#x000b1;&#x02009;standard deviation, and comparisons were conducted using the <italic>t</italic>-test. Categorical data, such as sex, are presented as percentages (%), with comparisons made using the chi-squared test. A <italic>post-hoc</italic> power analysis was performed using GPower software, indicating that our sample size provided sufficient power for detecting significant differences.</p><p>Binary logistic regression analysis was used to identify independent prognostic risk factors in patients with cardiogenic shock treated with extracorporeal membrane oxygenation. ROC curve analysis was conducted using MedCalc version 22 to assess the predictive performance of the indicators. Pearson correlation analysis was applied to examine the relationships between relevant parameters. A <italic>p</italic>-value of &#x0003c;0.05 was considered statistically significant.</p></sec></sec><sec sec-type="results" id="s3"><label>3</label><title>Results</title><sec id="s3a"><label>3.1</label><title>Comparison of general data of patients</title><p>Lactate clearance was significantly lower in the non-survival group compared to the survival group, while fluid balance and APACHE II scores were significantly higher in the non-survival group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). No statistically significant differences were observed in other relevant indices between the two groups (<italic>p</italic>&#x02009;&#x0003e;&#x02009;0.05) (<xref rid="T1" ref-type="table">Table&#x000a0;1</xref>).</p></sec><sec id="s3b"><label>3.2</label><title>Multivariate logistic regression analysis of the prognosis</title><p>Based on multivariate analysis, the APACHE II score, lactate clearance, and fluid balance were identified as independent risk factors for patients with cardiogenic shock undergoing extracorporeal membrane oxygenation (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) (<xref rid="T2" ref-type="table">Table&#x000a0;2</xref>).</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Prognostic multivariate logistic regression analysis.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="2" colspan="1">Variables</th><th valign="top" align="center" rowspan="2" colspan="1"><italic>B-</italic>value</th><th valign="top" align="center" rowspan="2" colspan="1">Standard error</th><th valign="top" align="center" rowspan="2" colspan="1">Wald</th><th valign="top" align="center" rowspan="2" colspan="1"><italic>p-</italic>value</th><th valign="top" align="center" colspan="2" rowspan="1">95% CI</th></tr><tr><th valign="top" align="center" rowspan="1" colspan="1">Lower limit</th><th valign="top" align="center" rowspan="1" colspan="1">Upper limit</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Lactate clearance (%)</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.206</td><td valign="top" align="center" rowspan="1" colspan="1">0.074</td><td valign="top" align="center" rowspan="1" colspan="1">7.827</td><td valign="top" align="center" rowspan="1" colspan="1">0.005</td><td valign="top" align="center" rowspan="1" colspan="1">0.705</td><td valign="top" align="center" rowspan="1" colspan="1">0.940</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fluid balance (ml/kg)</td><td valign="top" align="center" rowspan="1" colspan="1">0.282</td><td valign="top" align="center" rowspan="1" colspan="1">0.124</td><td valign="top" align="center" rowspan="1" colspan="1">5.142</td><td valign="top" align="center" rowspan="1" colspan="1">0.023</td><td valign="top" align="center" rowspan="1" colspan="1">1.039</td><td valign="top" align="center" rowspan="1" colspan="1">1.692</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">APACHE II score (points)</td><td valign="top" align="center" rowspan="1" colspan="1">0.917</td><td valign="top" align="center" rowspan="1" colspan="1">0.330</td><td valign="top" align="center" rowspan="1" colspan="1">7.721</td><td valign="top" align="center" rowspan="1" colspan="1">0.005</td><td valign="top" align="center" rowspan="1" colspan="1">1.310</td><td valign="top" align="center" rowspan="1" colspan="1">4.778</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Constant</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;13.557</td><td valign="top" align="center" rowspan="1" colspan="1">5.471</td><td valign="top" align="center" rowspan="1" colspan="1">6.141</td><td valign="top" align="center" rowspan="1" colspan="1">0.013</td><td valign="top" align="center" colspan="2" rowspan="1">-</td></tr></tbody></table></table-wrap></sec><sec id="s3c"><label>3.3</label><title>Analysis of the prognostic value of APACHE &#x02161; score, lactate clearance and fluid balance</title><p>The ROC curve analysis demonstrated that the APACHE II score exhibited the highest prognostic prediction specificity at 97.4%. Additionally, the combined detection approach achieved a significantly higher sensitivity of 95.5% compared to the use of single indices (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) (<xref rid="T3" ref-type="table">Table&#x000a0;3</xref> and <xref rid="F1" ref-type="fig">Figure&#x000a0;1</xref>).</p><table-wrap position="float" id="T3"><label>Table 3</label><caption><p>Examination of the APACHE II score, lactate clearance, and fluid balance prognostic values.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Variables</th><th valign="top" align="center" rowspan="1" colspan="1">AUC</th><th valign="top" align="center" rowspan="1" colspan="1">SE</th><th valign="top" align="center" rowspan="1" colspan="1">95%CI</th><th valign="top" align="center" rowspan="1" colspan="1">Sensitivity</th><th valign="top" align="center" rowspan="1" colspan="1">Specificity</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Lactate clearance (%)</td><td valign="top" align="center" rowspan="1" colspan="1">0.871</td><td valign="top" align="center" rowspan="1" colspan="1">0.0462</td><td valign="top" align="center" rowspan="1" colspan="1">0.760&#x0223c;0.944</td><td valign="top" align="center" rowspan="1" colspan="1">77.3</td><td valign="top" align="center" rowspan="1" colspan="1">84.2</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fluid balance (ml/kg)</td><td valign="top" align="center" rowspan="1" colspan="1">0.690</td><td valign="top" align="center" rowspan="1" colspan="1">0.0710</td><td valign="top" align="center" rowspan="1" colspan="1">0.557&#x0223c;0.803</td><td valign="top" align="center" rowspan="1" colspan="1">50.0</td><td valign="top" align="center" rowspan="1" colspan="1">81.6</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">APACHE II score (points)</td><td valign="top" align="center" rowspan="1" colspan="1">0.860</td><td valign="top" align="center" rowspan="1" colspan="1">0.0540</td><td valign="top" align="center" rowspan="1" colspan="1">0.746&#x0223c;0.936</td><td valign="top" align="center" rowspan="1" colspan="1">72.7</td><td valign="top" align="center" rowspan="1" colspan="1">97.4</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Combined detection</td><td valign="top" align="center" rowspan="1" colspan="1">0.980</td><td valign="top" align="center" rowspan="1" colspan="1">0.0145</td><td valign="top" align="center" rowspan="1" colspan="1">0.905&#x0223c;0.999</td><td valign="top" align="center" rowspan="1" colspan="1">95.5</td><td valign="top" align="center" rowspan="1" colspan="1">94.7</td></tr></tbody></table></table-wrap><fig position="float" id="F1"><label>Figure 1</label><caption><p>Receiver operating characteristic (ROC) curves for the prognostic prediction of cardiogenic shock outcomes based on lactate clearance, fluid balance, and APACHE II score. The combined model exhibited the highest predictive sensitivity.</p></caption><graphic xlink:href="fcvm-12-1557909-g001" position="float"/></fig></sec><sec id="s3d"><label>3.4</label><title>Correlation analysis of APACHE &#x02161; score, lactate clearance, and fluid balance</title><p>Pearson's correlation analysis revealed a negative correlation between lactate clearance and both fluid balance and the APACHE II score (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) (<xref rid="T4" ref-type="table">Table&#x000a0;4</xref>).</p><table-wrap position="float" id="T4"><label>Table 4</label><caption><p>Analysis of the correlation between fluid balance, lactate clearance, and APACHE II score.</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">Item</th><th valign="top" align="center" rowspan="1" colspan="1">Lactate clearance (%)</th><th valign="top" align="center" rowspan="1" colspan="1">Fluid balance (ml/kg)</th><th valign="top" align="center" rowspan="1" colspan="1">APACHE II score (points)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Lactate clearance (%)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.186</td><td valign="top" align="center" rowspan="1" colspan="1">&#x02212;0.276<xref rid="table-fn1" ref-type="table-fn"><sup>a</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fluid balance (ml/kg)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.164</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">APACHE II score (points)</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">1</td></tr></tbody></table><table-wrap-foot><fn id="table-fn1"><label>
<sup>a</sup>
</label><p>indicates that the correlation is significant at the 0.05 level (two-tailed).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3e"><label>3.5</label><title>Subgroup analysis using cox regression model</title><p>Exploratory subgroup analysis revealed that hypertensive patients exhibited a hazard ratio of 2.74 (95% CI: 0.156&#x02013;48.1), though statistical significance was not achieved (<italic>p</italic>-value&#x02009;=&#x02009;0.368). Patients with coronary artery disease showed no significant prognostic differences compared to those without (<xref rid="F2" ref-type="fig">Figure&#x000a0;2</xref>). Comorbidities such as coronary artery disease and hypertension were recorded, and their specific impact on outcomes was analyzed using cox regression model demonstrated in the subgroup analysis. The results suggested that the two comorbidities did not influence the survival in our data.</p><fig position="float" id="F2"><label>Figure 2</label><caption><p>Subgroup analysis results using cox regression model.</p></caption><graphic xlink:href="fcvm-12-1557909-g002" position="float"/></fig></sec></sec><sec sec-type="discussion" id="s4"><label>4</label><title>Discussion</title><p>Cardiogenic shock, characterized by multi-organ dysfunction resulting from a sudden decrease in cardiac output and reduced tissue perfusion, is associated with rapid onset and poor prognosis (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>). In the early stages, the disease commonly presents with hypotension and impaired consciousness, which can progress to loss of consciousness and adverse outcomes if left untreated (<xref rid="B10" ref-type="bibr">10</xref>). ECMO is recognized as an effective therapeutic intervention for such patients. However, clinical observations have highlighted that prognosis is influenced by multiple factors, necessitating a focus on the development of comprehensive prognostic assessment methods (<xref rid="B11" ref-type="bibr">11</xref>).</p><p>The findings of this study indicate that lactate clearance was significantly lower in the non-survival group compared to the survival group, while fluid balance and APACHE II scores were notably higher in the non-survival group (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). Moreover, lactate clearance, fluid balance, and APACHE II score were identified as independent prognostic risk factors for patients with cardiogenic shock undergoing ECMO (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). These results align with those reported by Li et al., and the following mechanisms may explain these findings (<xref rid="B12" ref-type="bibr">12</xref>). While individual indicators have been studied previously, our work uniquely integrates lactate clearance, fluid balance, and APACHE II score to provide a comprehensive prognostic model, demonstrating improved predictive accuracy.</p><p>Patients with cardiogenic shock often exhibit impaired tissue perfusion, leading to microcirculatory disturbances. Arterial blood lactate levels serve as a sensitive marker for tissue ischemia and hypoxia, reflecting the adequacy of oxygen supply and perfusion. Although a single lactate measurement provides useful insights, dynamic changes in lactate levels offer greater prognostic value. In this study, lactate clearance was used as a prognostic indicator. Higher lactate clearance levels were associated with improved responsiveness to ECMO therapy and significant alleviation of ischemic and hypoxic conditions. Patients in the survival group demonstrated effective circulation under ECMO support, ensuring adequate perfusion of vital organs and enhancing lactate clearance efficiency. Conversely, patients in the non-survival group experienced excessive ventricular preload, severe tissue ischemia, and persistent elevated arterial lactate levels, which were not effectively resolved, ultimately leading to unfavorable outcomes.</p><p>Fluid balance is another critical factor influencing prognosis in patients who are critically ill. In the initial stages of treatment, patients with cardiogenic shock often require substantial fluid resuscitation to maintain cardiopulmonary bypass. However, these patients are at risk of developing acute kidney injury due to volume depletion, which can result in fluid accumulation. In the survival group, effective ECMO therapy stabilized cardiopulmonary bypass, alleviated renal dysfunction, and restored fluid balance. In contrast, the non-survival group experienced persistent systemic circulatory and renal dysfunction, leading to fluid imbalance and poor outcomes.</p><p>The APACHE II score, a widely used measure of disease severity in patients who are critically ill, was positively correlated with prognosis.</p><p>The findings of this study revealed that the APACHE II score demonstrated the highest predictive specificity at 97.4%, while the combined indices exhibited the highest predictive sensitivity at 95.5% and a specificity of 94.7%. The use of a single index for prognosis is influenced by individual variability within the patient population, whereas a combined evaluation approach effectively mitigates this limitation, enabling a more comprehensive assessment of patient outcomes.</p><p>Additionally, a negative correlation between lactate clearance and both fluid balance and APACHE II score (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05) was identified. Lactate serves as a critical marker for tissue and organ hypoxia, with lactate levels positively correlating with disease severity. Lactate clearance reflects the resolution of lactate accumulation in the patient's circulatory system. During the initial stages of treatment, blood lactate levels are typically elevated. In patients who respond favorably to ECMO therapy, lactate accumulation progressively decreases, resulting in a high lactate clearance rate. Conversely, patients experiencing prolonged fluid retention and critical diseases exhibit impaired lactate clearance, characterized by a high APACHE II score, elevated fluid balance, and low lactate clearance levels.</p><p>However, this study has several limitations. Firstly, data on the presence of underlying comorbidities were not collected, making it unclear whether these conditions influenced patient prognosis. Despite rigorous statistical analysis, some confounding variables such as medication history and pre-existing conditions may have influenced the results. Subgroup analysis suggests hypertension may influence prognosis, though further validation is needed due to wide confidence intervals. Future studies with larger cohorts should explore these relationships more robustly. Second, the study population consisted of patients with relatively similar age profiles, limiting the ability to explore the prognostic differences between younger, middle-aged, and older adult patients. Finally, the small sample size may have introduced statistical bias, potentially leading to missing or inconclusive data. Another key limitation of this study is its retrospective nature, which may introduce selection bias. Additionally, the small sample size may affect the statistical robustness of our findings. Future studies with larger sample sizes and prospective validation are warranted. The study also did not comprehensively analyze the influence of pre-existing comorbidities due to lack of data, which could have affected patient outcomes. Central venous oxygen saturation data were also not included. Future studies should focus on addressing these limitations by incorporating a larger and more diverse sample size, accounting for the presence of underlying comorbidities, and examining prognostic variations across different age groups. Such efforts will enable more comprehensive findings and contribute to the advancement of high-quality medical services.</p><p>In conclusion, this pilot study demonstrates that lactate clearance, fluid balance, and the APACHE II score are valuable indicators for prognostic evaluation in patients with cardiogenic shock undergoing ECMO. Furthermore, the combined assessment of these indices exhibited superior efficacy compared to single-index evaluations. The findings presented here highlight the need for a more comprehensive investigation into the role of lactate clearance, fluid balance, and the APACHE II score in guiding clinical decision-making.</p></sec></body><back><fn-group><title>Abbreviations</title><fn fn-type="abbr" id="ab001"><p>APACHE II, acute physiology and chronic health evaluation; SOFA, sequential organ failure assessment; PH, potential of hydrogen; ROC, receiver operating characteristic.</p></fn></fn-group><sec sec-type="data-availability" id="s5"><title>Data availability statement</title><p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p></sec><sec sec-type="ethics-statement" id="s6"><title>Ethics statement</title><p>The studies involving humans were approved by this study was conducted in accordance with the declaration of Helsinki.This study was conducted with approval from the Ethics Committee of Peking University International Hospital (2024-KY-0048-01). A written informed consent was obtained from all participants. The studies were conducted in accordance with the local legislation and institutional requirements. The participants provided their written informed consent to participate in this study.</p></sec><sec sec-type="author-contributions" id="s7"><title>Author contributions</title><p>Q-FZ: Conceptualization, Data curation, Formal analysis, Funding acquisition, Writing &#x02013; original draft, Writing &#x02013; review &#x00026; editing. S-LZ: Conceptualization, Data curation, Writing &#x02013; review &#x00026; editing. GL: Conceptualization, Formal analysis, Writing &#x02013; review &#x00026; editing. MG: Conceptualization, Data curation, Writing &#x02013; review &#x00026; editing. X-XQ: Conceptualization, Data curation, Writing &#x02013; review &#x00026; editing. X-HX: Conceptualization, Data curation, Writing &#x02013; review &#x00026; editing. ZW: Conceptualization, Formal analysis, Writing &#x02013; review &#x00026; editing.</p></sec><sec sec-type="COI-statement" id="s9"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="ai-statement" id="s10"><title>Generative AI statement</title><p>The author(s) declare that no Generative AI was used in the creation of this manuscript.</p></sec><sec sec-type="disclaimer" id="s11"><title>Publisher's note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garc&#x000ed;a-Garc&#x000ed;a</surname><given-names>C</given-names></name><name><surname>L&#x000f3;pez-Sobrino</surname><given-names>T</given-names></name><name><surname>Sanz-Girgas</surname><given-names>E</given-names></name><name><surname>Cueto</surname><given-names>MR</given-names></name><name><surname>Aboal</surname><given-names>J</given-names></name><name><surname>Pastor</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Cardiogenic shock mortality according to aetiology in a Mediterranean cohort: results from the Shock-CAT study</article-title>. <source>ESC Heart Fail</source>. (<year>2025</year>) <volume>12</volume>(<issue>2</issue>):<fpage>1336</fpage>&#x02013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1002/ehf2.15148</pub-id><pub-id pub-id-type="pmid">39587711</pub-id>
</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siopi</surname><given-names>SA</given-names></name><name><surname>Antonitsis</surname><given-names>P</given-names></name><name><surname>Karapanagiotidis</surname><given-names>GT</given-names></name><name><surname>Tagarakis</surname><given-names>G</given-names></name><name><surname>Voucharas</surname><given-names>C</given-names></name><name><surname>Anastasiadis</surname><given-names>K</given-names></name></person-group>. <article-title>Cardiac failure and cardiogenic shock: insights into pathophysiology, classification, and hemodynamic assessment</article-title>. <source>Cureus</source>. (<year>2024</year>) <volume>16</volume>(<issue>10</issue>):<fpage>e72106</fpage>. <pub-id pub-id-type="doi">10.7759/cureus.72106</pub-id><pub-id pub-id-type="pmid">39575019</pub-id>
</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kunkel</surname><given-names>JB</given-names></name><name><surname>Holle</surname><given-names>SLD</given-names></name><name><surname>Hassager</surname><given-names>C</given-names></name><name><surname>Pecini</surname><given-names>R</given-names></name><name><surname>Wiberg</surname><given-names>S</given-names></name><name><surname>Palm</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Interleukin-6 receptor antibodies (tocilizumab) in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (DOBERMANN-T): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial</article-title>. <source>Trials</source>. (<year>2024</year>) <volume>25</volume>(<issue>1</issue>):<fpage>739</fpage>. <pub-id pub-id-type="doi">10.1186/s13063-024-08573-0</pub-id><pub-id pub-id-type="pmid">39501388</pub-id>
</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holle</surname><given-names>SLD</given-names></name><name><surname>Kunkel</surname><given-names>JB</given-names></name><name><surname>Hassager</surname><given-names>C</given-names></name><name><surname>Pecini</surname><given-names>R</given-names></name><name><surname>Wiberg</surname><given-names>S</given-names></name><name><surname>Palm</surname><given-names>P</given-names></name><etal/></person-group>
<article-title>Low-dose dobutamine in acute myocardial infarction with intermediate to high risk of cardiogenic shock development (the DOBERMANN-D trial): study protocol for a double-blinded, placebo-controlled, single-center, randomized clinical trial</article-title>. <source>Trials</source>. (<year>2024</year>) <volume>25</volume>(<issue>1</issue>):<fpage>731</fpage>. <pub-id pub-id-type="doi">10.1186/s13063-024-08567-y</pub-id><pub-id pub-id-type="pmid">39478521</pub-id>
</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><collab>Cardiovascular Emergency and Critical Care Group, Cardiovascular Disease Branch, Chinese Medical Association, Editorial Committee of Chinese Journal of Cardiovascular Disease</collab>. <article-title>Chinese expert consensus on diagnosis and treatment of cardiogenic shock (2018)</article-title>. <source>Chin J Cardiovasc Dis</source>. (<year>2019</year>) <volume>47</volume>(<issue>4</issue>):<fpage>265</fpage>&#x02013;<lpage>77</lpage>. <pub-id pub-id-type="doi">10.3760/cma.j.issn.0253-3758.2019.04.003</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>JL</given-names></name><name><surname>Moreno</surname><given-names>R</given-names></name><name><surname>Takala</surname><given-names>J</given-names></name><name><surname>Willatts</surname><given-names>S</given-names></name><name><surname>De Mendon&#x000e7;a</surname><given-names>A</given-names></name><name><surname>Bruining</surname><given-names>H</given-names></name><etal/></person-group>
<article-title>The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure</article-title>. <source>Intensive Care Med</source>. (<year>1996</year>) <volume>22</volume>(<issue>7</issue>):<fpage>707</fpage>&#x02013;<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1007/BF01709751</pub-id><pub-id pub-id-type="pmid">8844239</pub-id>
</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Polderman</surname><given-names>KH</given-names></name><name><surname>Girbes</surname><given-names>AR</given-names></name><name><surname>Thijs</surname><given-names>LG</given-names></name><name><surname>Strack van Schijndel</surname><given-names>RJ</given-names></name></person-group>. <article-title>Accuracy and reliability of APACHE II scoring in two intensive care units: problems and pitfalls in the use of APACHE II and suggestions for improvement</article-title>. <source>Anaesthesia</source>. (<year>2001</year>) <volume>56</volume>(<issue>1</issue>):<fpage>47</fpage>&#x02013;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1046/j.1365-2044.2001.01763.x</pub-id><pub-id pub-id-type="pmid">11167435</pub-id>
</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motovska</surname><given-names>Z</given-names></name><name><surname>Hlinomaz</surname><given-names>O</given-names></name><name><surname>Mrozek</surname><given-names>J</given-names></name><name><surname>Kala</surname><given-names>P</given-names></name><name><surname>Geisler</surname><given-names>T</given-names></name><name><surname>Hromadka</surname><given-names>M</given-names></name><etal/></person-group>
<article-title>Cangrelor versus crushed ticagrelor in patients with acute myocardial infarction and cardiogenic shock: rationale and design of the randomised, double-blind DAPT-SHOCK-AMI trial</article-title>. <source>EuroIntervention</source>. (<year>2024</year>) <volume>20</volume>(<issue>20</issue>):<fpage>e1309</fpage>&#x02013;<lpage>18</lpage>. <pub-id pub-id-type="doi">10.4244/EIJ-D-24-00203</pub-id><pub-id pub-id-type="pmid">39432252</pub-id>
</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schupp</surname><given-names>T</given-names></name><name><surname>Thiele</surname><given-names>H</given-names></name><name><surname>Rassaf</surname><given-names>T</given-names></name><name><surname>Mahabadi</surname><given-names>AA</given-names></name><name><surname>Lehmann</surname><given-names>R</given-names></name><name><surname>Eitel</surname><given-names>I</given-names></name><etal/></person-group>
<article-title>Prognostic impact of admission time in infarct-related cardiogenic shock: an ECLS-SHOCK substudy</article-title>. <source>JACC Cardiovasc Interv</source>. (<year>2024</year>) <volume>17</volume>(<issue>19</issue>):<fpage>2228</fpage>&#x02013;<lpage>39</lpage>. <pub-id pub-id-type="doi">10.1016/j.jcin.2024.08.013</pub-id><pub-id pub-id-type="pmid">39415381</pub-id>
</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rymer</surname><given-names>J</given-names></name><name><surname>Pichan</surname><given-names>C</given-names></name><name><surname>Page</surname><given-names>C</given-names></name><name><surname>Alhanti</surname><given-names>B</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Kochar</surname><given-names>A</given-names></name><etal/></person-group>
<article-title>The use of cangrelor in cardiogenic shock: insights from the CAMEO registry</article-title>. <source>J Card Fail</source>. (<year>2024</year>) <volume>30</volume>(<issue>10</issue>):<fpage>1233</fpage>&#x02013;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.cardfail.2024.08.003</pub-id><pub-id pub-id-type="pmid">39389732</pub-id>
</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pang</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Shi</surname><given-names>B</given-names></name><etal/></person-group>
<article-title>The CMLA score: a novel tool for early prediction of renal replacement therapy in patients with cardiogenic shock</article-title>. <source>Curr Probl Cardiol</source>. (<year>2024</year>) <volume>49</volume>(<issue>12</issue>):<fpage>102870</fpage>. <pub-id pub-id-type="doi">10.1016/j.cpcardiol.2024.102870</pub-id><pub-id pub-id-type="pmid">39343053</pub-id>
</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name></person-group>. <article-title>Predictive value of IABP-SHOCK II score combined with arterial lactate and red cell distribution width for prognosis in myocardial infarction complicated by cardiogenic shock</article-title>. <source>Lab Med Clin Pract</source>. (<year>2023</year>) <volume>20</volume>(<issue>18</issue>):<fpage>2725</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref></ref-list></back></article>